盐酸拓扑替康(金喜素)联合顺铂治疗70例初治小细胞肺癌临床观察  

Topotecan Hydrochloride Plus DDP in the Initial Treatment of Small Cell Lung Cancer: Observation of 70 Cases

作　　者：宫辉[1] 

机构地区：[1]辽宁省肿瘤医院,沈阳市110042

出　　处：《中国医院用药评价与分析》2007年第1期70-71,共2页Evaluation and Analysis of Drug-use in Hospitals of China

摘　　要：目的:评价盐酸拓扑替康+顺铂治疗小细胞肺癌的疗效和不良反应。方法:治疗初治小细胞肺癌70例,盐酸拓扑替康0.75mg/m2,静脉滴注d1～5,顺铂20mg/m2dl～3,每4周重复疗程。结果:CR11例(16.7%)PR36例(51.4%),NC23例(32.9%),PD3例(4.3%)。结论:盐酸拓扑替康+顺铂治疗初治小细胞肺癌安全有效。OBJECTIVE： To evaluate the curative effect and toxicity of topotecan hydrochioride plus DDP for small cell lung cancer （SCLC）. METHODS： 70 patients with SCLC were treated with topotecan hydrochlofide 0.75mg/m^2 iv gtt from day 1 to day 5 and DDP 20mg/m^2 iv gtt from day 1 to day 3. Course of treatment was repeated every 4 weeks. RESULTS： Therewere 11 CR cases （16.7%）, 36 PR cases （51.4%）, 23 NC cases （32.9%） and 3 PD cases （4.3%） . CONCLUSION： Topotecan hydrochloride plus DDP is safe and effective in the treatment of SCLC.

关 键 词：盐酸拓扑替康 顺铂 联合化疗 小细胞肺癌 

分 类 号：R979.1[医药卫生—药品]